{"id":750079,"date":"2023-04-21T16:03:02","date_gmt":"2023-04-21T20:03:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/"},"modified":"2023-04-21T16:03:02","modified_gmt":"2023-04-21T20:03:02","slug":"arvinas-to-present-at-stifel-targeted-oncology-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/","title":{"rendered":"Arvinas to Present at Stifel Targeted Oncology Day"},"content":{"rendered":"
\n

NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET.<\/p>\n

A live audio webcast of the fireside chat will be available here<\/a> and on the Events & Presentations section of the Investors & Media section of the Company\u2019s website.<\/p>\n

\n About\u00a0Arvinas<\/strong>
\n
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC\u00ae<\/sup>\u00a0Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC\u00ae<\/sup>\u00a0targeted protein degraders, that are designed to harness the body\u2019s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC\u00ae<\/sup>\u00a0protein degraders against validated and \u201cundruggable\u201d targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+\/HER2- breast cancer. For more information, visit\u00a0www.arvinas.com<\/strong><\/a>.<\/p>\n

\n Contacts<\/strong>
\n
\n Investors:<\/strong>
\n
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com<\/strong><\/a><\/p>\n

\n Media:<\/strong>
\n
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com<\/strong><\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET. A live audio webcast of the fireside chat will be available here and on the Events & Presentations section of the Investors & Media section of the Company\u2019s website. About\u00a0Arvinas Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that … <\/p>\n

Continue reading “Arvinas to Present at Stifel Targeted Oncology Day”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750079","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArvinas to Present at Stifel Targeted Oncology Day - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas to Present at Stifel Targeted Oncology Day - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET. A live audio webcast of the fireside chat will be available here and on the Events & Presentations section of the Investors & Media section of the Company\u2019s website. About\u00a0Arvinas Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that … Continue reading "Arvinas to Present at Stifel Targeted Oncology Day"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T20:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas to Present at Stifel Targeted Oncology Day\",\"datePublished\":\"2023-04-21T20:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/\"},\"wordCount\":248,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/\",\"name\":\"Arvinas to Present at Stifel Targeted Oncology Day - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=\",\"datePublished\":\"2023-04-21T20:03:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-at-stifel-targeted-oncology-day\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas to Present at Stifel Targeted Oncology Day\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas to Present at Stifel Targeted Oncology Day - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas to Present at Stifel Targeted Oncology Day - Market Newsdesk","og_description":"NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET. A live audio webcast of the fireside chat will be available here and on the Events & Presentations section of the Investors & Media section of the Company\u2019s website. About\u00a0Arvinas Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that … Continue reading \"Arvinas to Present at Stifel Targeted Oncology Day\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-21T20:03:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas to Present at Stifel Targeted Oncology Day","datePublished":"2023-04-21T20:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/"},"wordCount":248,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/","name":"Arvinas to Present at Stifel Targeted Oncology Day - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=","datePublished":"2023-04-21T20:03:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMzE0NiM1NTQwNzA1IzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-at-stifel-targeted-oncology-day\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas to Present at Stifel Targeted Oncology Day"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750079"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750079\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}